GSK Launches First Once-Daily Triple Therapy for COPD, Trelegy Ellipta, on Alibaba Health Platform

Shanghai, March 29, 2020 /PRNewswire/ -- GlaxoSmithKline (GSK) announced today that itsThe World's FirstTrelegy, a once-daily triple inhalation therapy for the maintenance treatment of stable COPD^® Ellipta^®) (Generic Name: Fluticasone Furoate/Umeclidinium/Vilanterol Inhalation Powder, 100/62.5/25 mcg)mcg) launched exclusively on the AliHealth platform. By leveraging “Internet + Healthcare” technologies and online platform resources, GSK will further expand the accessibility of Trelegy in the Chinese market, meeting the medication and diagnostic and treatment needs of a broad population of patients with chronic obstructive pulmonary disease (COPD).

Trelegy was officially approved for marketing in China in November 2019. This inhalation preparation is indicated for the maintenance treatment of stable chronic obstructive pulmonary disease (COPD) and contains an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-actingβ2Receptor agonist (LABA) three drug components, through GSK's unique Ellipta^®) Administered once daily via a dry powder inhaler.

Chronic Obstructive Pulmonary Disease (COPD) is the third most common chronic disease in China, after hypertension and diabetes.^[1]. The latest data show that nearly 100 million people in China are affected by chronic obstructive pulmonary disease (COPD), and the prevalence of COPD has increased significantly in recent years due to low awareness and diagnosis rates. ^[2,3], has become the third leading cause of death among residents in China^[4]. Similar to the management of other chronic diseases, patients with chronic obstructive pulmonary disease (COPD) require long-term adherence to standardized medication regimens to achieve stable outcomes.

With the deep integration of internet technology and healthcare services, the “Healthy China” strategy further emphasizes the development of convenient and beneficial “Internet + Healthcare” services, achieving a new model of informatized and standardized chronic disease management by improving the “Internet +” drug supply guarantee.^[5]Amid the severe situation of the novel coronavirus pneumonia (abbreviated as "COVID-19") epidemic, the online diagnosis and treatment model for chronic diseases, accelerated by "Internet+" technology, has further highlighted its advantages. Leveraging the "Internet + Healthcare" trend, GSK and AliHealth have also launched a "Chronic Disease Service Program" for patients with chronic hepatitis B, asthma, and chronic obstructive pulmonary disease (COPD), providing comprehensive support and supply for medication needs related to these conditions on online health platforms, thereby helping patients manage their diseases more safely and effectively. In addition, GSK will reduce the supply price of Trelegy to expand patient accessibility, particularly enabling more patients to benefit from this innovative product during the epidemic.

Zhu Shunyan, CEO of AliHealth, stated, “During the pandemic, we collaborated with more than 50 renowned pharmaceutical companies both domestically and internationally to launch the ‘Medication Without Leaving Home’ initiative, enabling patients with chronic diseases to purchase medications on Tmall, receive online follow-up consultations, and have their prescriptions delivered to their doorsteps. Chronic obstructive pulmonary disease (COPD) is the third most prevalent chronic disease in China. Trelegy, the triple-inhaler therapy introduced by GSK for Chinese patients, is also the first COPD triple therapy globally approved for once-daily dosing. We believe that through our joint efforts, we can provide COPD patients with a seamless end-to-end service experience, encompassing online follow-up consultations and prescription renewals, product delivery, and online medication management.”

Qi Xin, General Manager of GSK China’s Prescription Drugs and Vaccines division, stated, “GSK has always been committed to supporting the Chinese government’s major initiatives in healthcare reform. Leveraging our own strengths and the power of the Alibaba ecosystem, we will actively explore innovative ‘Internet + Healthcare’ service models to help address disease management and medical challenges for patients with chronic diseases in China. Trelegy is the first once-daily triple therapy for COPD approved by GSK in China, embodying the company’s years of innovation in the field of COPD treatment. The availability of Trelegy on the AliHealth platform will provide COPD patients with broader and more convenient access to medication. In the future, we will continue to strengthen our collaboration with internet platforms to effectively improve drug accessibility and benefit more patients.”

FF/UMEC/VIofSafety Information

Clinical studies have demonstrated that FF/UMEC/VI has a favorable overall safety profile, comparable to that of ICS/LABA and LAMA/LABA formulations. No new safety concerns have been identified associated with the combined use of inhaled corticosteroids, LAMAs, and LABAs.^[6.7]。

GSKRespiratory Health Commitment

For 50 years, GSK has been a pioneer in the development of medications for asthma and chronic obstructive pulmonary disease (COPD). From launching the world’s first selective short-acting beta-agonist in 1969 to introducing six therapeutic regimens within five years, GSK has built today’s industry-leading respiratory portfolio. We continue to innovate, delivering the right treatments to the right patients. Collaborating with stakeholders across the healthcare community, we leverage world-class science and innovation to identify and rigorously investigate promising molecules that may become future medicines. Our commitment to innovation remains unwavering; we will not rest until everyone can breathe easily.

GSK- is a global leader in research-based pharmaceuticals and healthcare. Committed to enabling people to do more, feel better, and live longer. For more information, please visitwww.gsk.com。

References:

1. Wang C. et al. The Lancet 2018; S0140-6736(18)30841-9.

2. Zhong N, et al. Am J Respir Crit Care Med. 2007;176(8):753-760.

3. Wang C. et al. The Lancet 2018; 391 (10131).

4. Zhou M, et al. Lancet. 2019 Jun 24. pii S0140-6736(19)30427-1.

5. Opinions of the General Office of the State Council on Promoting the Development of “Internet + Healthcare”

6. Lipson DA, et al. Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446.

7. Lipson DA, et al. N Engl J Med. 2018;378:1671–1680.